PR Newswire BiotechOriginal article
Clinical Update from the Ongoing Phase 2 Trial of PRV111, the First Non-Surgical Therapy in Development for Early-Stage Oral Cancer
Phase 2positivePRV111Positive
AI Analysis
Summary
Provectus Biopharmaceuticals announced Phase 2 trial results for PRV111, a non-surgical therapy for early-stage oral cancer, showing a 95.5% pathologic complete response rate with 21 of 22 evaluable patients achieving centrally confirmed pCR following a single cycle.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Patients
22
Outcome Details
95.5% pathologic complete response rate (21 of 22 evaluable patients achieved centrally confirmed pCR; remaining patient downstaged from oral carcinoma in situ to lower stage)
Importance:7/10
Sentiment:
0.85
Phase 2 dataoral cancerpathologic complete responsenon-surgical therapyclinical update
Related Companies
Read the original article
Published by PR Newswire Biotech on October 5, 2026 2:00 PM